Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

EXCLUSIVE: Sunshine Biopharma's Newly Designed mRNA Molecules Effective Against Multidrug Resistant Cancer Cells

Oncology and antiviral drugs focused Sunshine Biopharma Inc (NASDAQ:SBFM) has said that two of its newly designed mRNA molecules can effectively destroy cancer cells grown in culture. 

What Happened: The cytotoxicity tests were performed on various cancer cells, including multidrug-resistant breast cancer cells, ovarian adenocarcinoma cells, and pancreatic cancer cells. 

Toxicity studies using non-transformed (normal) human cells (HMEC cells) showed that these mRNA molecules had little or no cytotoxic effects. 

Why It’s Important: These new mRNA molecules are readily adaptable for delivery to patients using the mRNA vaccine technology. Sunshine Biopharma anticipates filing a patent application in connection with these results soon.

“The potential use of mRNA to treat cancer opens the door to many possibilities for patients, including convenience, reduced toxicity, and enhanced efficacy,” said Dr. Steve Slilaty, CEO.

Sunshine Biopharma is working on developing a treatment for COVID-19 and has completed the synthesis of four potential inhibitors of PLpro.

The Company is currently advancing SBFM-PL4 in collaboration with the University of Georgia, College of Pharmacy. 

Additionally, Sunshine is developing Adva-27a, an anti-cancer compound.

Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Canada.

Price Action: SBFM shares closed 1.31% lower at $2.26 on Monday.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.